Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Coiffier

Showing results (201-210 of 249) with videos related to

Pageof 25
Sort By:
Leukemia & Lymphoma|July 8, 2008
Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survivalCatherine Thieblemont, Delphine Rolland, Lucile Baseggio, et al.
American Journal of Hematology|April 11, 2012
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma ProjectZdravko Mitrovic, Anamarija M Perry, Junji Suzumiya, et al.
Blood|July 5, 2003
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeAnnarita Conconi, Giovanni Martinelli, Catherine Thiéblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulteEmmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma projectMassimo Federico, Thomas Rudiger, Monica Bellei, et al.
Blood|May 4, 2010
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA studyFabrice Jardin, Jean-Philippe Jais, Thierry-Jo Molina, et al.
Oncotarget|November 22, 2017
Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CTCédric Rossi, Morgane Mounier, Pauline Brice, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
British Journal of Haematology|March 25, 2016
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaBertrand Coiffier, Catherine Thieblemont, Sophie de Guibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Pageof 25

Showing results (201-210 of 249) with videos related to

Sort By:
Pageof 25
Leukemia & Lymphoma|July 8, 2008
Comprehensive analysis of GST-pi expression in B-cell lymphomas: Correlation with histological subtypes and survivalCatherine Thieblemont, Delphine Rolland, Lucile Baseggio, et al.
American Journal of Hematology|April 11, 2012
The prognostic significance of lymphopenia in peripheral T-cell and natural killer/T-cell lymphomas: a study of 826 cases from the International Peripheral T-cell Lymphoma ProjectZdravko Mitrovic, Anamarija M Perry, Junji Suzumiya, et al.
Blood|July 5, 2003
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT typeAnnarita Conconi, Giovanni Martinelli, Catherine Thiéblemont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulteEmmanuel Bachy, Pauline Brice, Richard Delarue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma projectMassimo Federico, Thomas Rudiger, Monica Bellei, et al.
Blood|May 4, 2010
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA studyFabrice Jardin, Jean-Philippe Jais, Thierry-Jo Molina, et al.
Oncotarget|November 22, 2017
Infradiaphragmatic Hodgkin lymphoma: a large series of patients staged with PET-CTCédric Rossi, Morgane Mounier, Pauline Brice, et al.
Journal of Hematology & Oncology|January 25, 2014
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responsesBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
British Journal of Haematology|March 25, 2016
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphomaBertrand Coiffier, Catherine Thieblemont, Sophie de Guibert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapyBertrand Coiffier, Barbara Pro, H Miles Prince, et al.
Pageof 25